METTL3-overexpressing H9c2 cells were also used to investigate SYD's effects on gene expression.<h4>Results</h4><i>In vivo</i>, SYD treatment significantly improved cardiac function in MI mice, including reduced cardiac hypertrophy, enhanced ejection fraction and fractional shortening, and alleviated myocardial damage, fibrosis, and HF biomarkers. The gene discussed is METTL3; the disease is cardiac hypertrophy.